CMET-07. VISMODEGIB TREATMENT OF INTRACRANIAL INVASION OF BASAL CELL CARCINOMA

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Vismodegib (erivedge) for advanced Basal cell carcinoma.

Vismodegib (Erivedge) for advanced basal cell carcinoma.

متن کامل

Emergence of Squamous Cell Carcinoma during Treatment of Basal Cell Carcinoma with Vismodegib

Basal cell carcinoma (BCC) accounts for 80% of all non-melanoma skin cancer [1]. Advanced disease is infrequently seen, but when present can be a surgical challenge or even life threatening. Recent studies show that mutations in the hedgehog (HH) signaling pathway are associated with the majority of BCC. Hedgehog protein binds to patched homologue 1 (PTCH1) transmembrane receptor, which prevent...

متن کامل

Intracranial regression of an advanced basal cell carcinoma using sonidegib and itraconazole after failure with vismodegib

BCC: basal cell carcinoma Hh: hedgehog HIV: human immunodeficiency virus SMO: smoothened protein INTRODUCTION Locally advanced or metastatic basal cell carcinoma (BCC) has traditionally been difficult to treat. Options for unresectable tumors have been limited to cisplatin-based chemotherapy or palliative radiation therapy. With the advent of molecularly targeted drugs to the hedgehog (Hh) path...

متن کامل

Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

BACKGROUND Alterations in hedgehog signaling are implicated in the pathogenesis of basal-cell carcinoma. Although most basal-cell carcinomas are treated surgically, no effective therapy exists for locally advanced or metastatic basal-cell carcinoma. A phase 1 study of vismodegib (GDC-0449), a first-in-class, small-molecule inhibitor of the hedgehog pathway, showed a 58% response rate among pati...

متن کامل

Vismodegib: the Proof of Concept in Basal Cell Carcinoma

Although basal cell carcinoma (BCC) is the most common cancer worldwide, its metastatic dissemination is exceptional. Before 2012, we had a few treatment options available for metastatic or locally advanced cases. Management of these patients was complicated due to the lack of scientific data, the deterioration of a patient's general status, the patient's advanced age, and the presence of multi...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Neuro-Oncology

سال: 2017

ISSN: 1522-8517,1523-5866

DOI: 10.1093/neuonc/nox168.156